Head and neck cancer (HNC) represents a heterogeneous group of malignancies with increasing global incidence and notable mortality. Early detection is essential for improving survival rates and minimizing recurrence; however, existing diagnostic methods are often invasive and complex. There is a need for noninvasive and more effective approaches for early detection and real-time monitoring of HNC. Saliva contains various biomolecules that may serve as indicators of HNC. As a result, saliva-based biomarkers have emerged as a transformative approach in the diagnosis and treatment of HNC due to their ease of collection, non-invasiveness, and potential to provide details about biomolecular changes associated with cancer progression. This narrative review synthesizes the current literature on the potential of saliva as a noninvasive diagnostic tool for HNC. It highlights various biomarkers found in saliva, including cell-free DNA, RNA, proteins, and metabolites, and explores emerging technologies in saliva detection that could transform the future of HNC management. Continued research efforts and larger-scale validation studies are essential to fully realize the potential of saliva-based biopsy and help pinpoint notable biomarkers to improve patient outcomes and reduce mortality associated with HNC worldwide.
Paraneoplastic cerebellar degeneration (PCD) is a rare neurological complication of malignancies, resulting from autoimmune responses targeting antigens shared by neurons and tumors. It is characterized by progressive cerebellar dysfunction, including ataxia and dysarthria, and is associated with anti-onconeuronal antibodies such as Anti-Yo and Anti-Hu. While most cases of Anti-Hu-associated PCD occur in patients with small cell lung cancer, their association with gynecologic malignancies is exceedingly rare. This is the first reported case in the literature of a patient with adenocarcinoma of Müllerian origin complicated by Anti-Hu PCD. We present the case of a 73-year-old female with stage IV adenocarcinoma of Müllerian origin who presented with worsening ataxia and dysarthria after undergoing outpatient chemoimmunotherapy to treat her gynecologic malignancy. CT and MRI Brain imaging revealed nonspecific findings, but cerebrospinal fluid (CSF) analysis revealed the presence of positive anti-Hu and anti-Zic4 antibodies, consistent with a diagnosis of PCD. Despite treatment with high-dose intravenous corticosteroids and plasmapheresis in the acute setting, the patient displayed minimal improvement and continued to experience persistent neurological impairment. Despite advancements in diagnostic criteria and the availability of multiple types of therapies, outcomes for PCD remain poor. This is especially notable for cases associated with Anti-Hu antibodies. This case highlights the importance of considering PCD in the differential diagnosis of patients with malignancies and unexplained neurological symptoms. Furthermore, it highlights the critical need for continued research to refine diagnostic methods and develop more effective, evidence-based treatment strategies to improve outcomes.
1 January 2025 in Case Reports in Gastrointestinal Medicine
Neuroendocrine tumors (NETs) are rare neoplasms composed of neuroendocrine cells and seen in approximately 2% of malignancies in the United States. These are often underdiagnosed due to nonspecific presentations early in the disease course. Although found primarily in the gastrointestinal tract, lungs, and pancreas, these tumors can be seen anywhere in the body. The following case highlights an unusual presentation of a NET and subsequent management of hepatic hydrothorax in the setting of obstruction rather than decompensated liver cirrhosis.
Background/Aim: Primary ocular adnexal lymphomas pose a diagnostic challenge for physicians due to their nonspecific symptom presentation and resemblance to other periorbital masses, such as skin and soft tissue infections. Early diagnosis and appropriate management are crucial for optimizing outcomes and coordination of therapy. Case Report: We present a case of a 67-year-old male with a history of infraorbital trauma, initially managed as a soft tissue infection, which was later revealed to be a large B-cell lymphoma. Despite multiple specialty evaluations, including dermatology, ophthalmology, plastic surgery, and ENT, among others, diagnosis was delayed, leading to worsening symptoms and vision impairment. Conclusion: This case highlights the importance of considering ocular adnexal lymphomas in the differential diagnosis of periorbital masses and the need for interdisciplinary collaboration for timely recognition and treatment.
Breast cancer is the most commonly diagnosed malignancy among women worldwide. While survival outcomes have improved substantially over time, recurrence remains a significant concern, especially in estrogen receptor-positive (ER+) disease. Although most recurrences occur within five years of initial treatment, ER+ tumors carry a persistent risk of late relapse due to tumor dormancy. Very late recurrences occurring decades after remission are rare and poorly characterized. We present the case of a 96-year-old female with a history of right-sided breast cancer treated with mastectomy and adjuvant radiation therapy at age 50, who presented 46 years later with a palpable chest wall mass near her prior mastectomy scar. Imaging revealed an irregular hypoechoic lesion extending into the pectoralis muscle (BIRADS-5). Core biopsy demonstrated moderately differentiated infiltrating lobular carcinoma that was strongly ER+, progesterone receptor-negative, and HER2 non-amplified. Staging studies revealed no evidence of distant metastatic disease. Given the patient's advanced age, comorbidities, and prior radiation exposure, surgical and radiation approaches were deferred. Following multidisciplinary tumor board discussion and shared decision-making, primary endocrine therapy with tamoxifen was initiated. The patient demonstrated clinical regression within three months and tolerated therapy well. This case represents one of the longest reported intervals between initial remission and breast cancer recurrence, highlighting the prolonged biologic potential of dormant ER-positive tumor cells. Clinicians should maintain vigilance for recurrence even decades after treatment, particularly in hormone receptor-positive disease.
Non-islet cell tumor hypoglycemia (NICTH) is a rare paraneoplastic syndrome associated with a variety of benign and malignant tumors. It is most commonly associated with tumors of epithelial or mesenchymal origin. Management of NICTH primarily involves resection of the underlying tumor, along with other therapies. We report a case of NICTH secondary to metastatic rectal adenocarcinoma. While NICTH has previously been associated with colorectal cancers, few cases (if any) have been reported in patients with primary rectal cancer. We present the case of a 51-year-old male with a medical history of pre-diabetes, gastroesophageal reflux disease, and tobacco use disorder. He was admitted for evaluation of rapid weight loss and was found to have rectal thickening, along with lesions in the lungs, liver, pancreas, and other sites, raising concern for metastasis. He underwent a colonoscopy with biopsy, which confirmed primary rectal adenocarcinoma. During his inpatient stay, he experienced recurrent episodes of hypoglycemia. A diagnosis of NICTH was supported by the low levels of pro-insulin, insulin, C-peptide, IGF-I and an elevated IGF-II:IGF-I ratio. The patient was treated with corticosteroids, glucagon, continuous dextrose infusions, and parenteral nutrition to manage hypoglycemia. This case highlights the importance of considering NICTH in the differential diagnosis for patients with unexplained or refractory hypoglycemia, especially when a notable mass or malignancy is suspected. It also highlights the need for a multimodal approach in managing the underlying hypoglycemia.